The ß-ARs play an important role in CV health and disease and are mainstay targets of ß blockers in the treatment of hypertension, congestive HF, and coronary disease. Both genetic association and ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The study found phenylacetylglutamine (PAG), produced by gut bacteria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results